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Abstract 
Targeted inactivations of RNA-binding proteins (RNA-BPs) can lead to huge phenotypical 
defects. These defects are due to the deregulation of certain mRNAs. However, we generally 
do not know, among the hundreds of mRNAs that are normally controlled by one RNA-BP, 
which are responsible for the observed phenotypes. Here, we designed an antisense 
oligonucleotide ("target protector") that masks the binding site of the RNA-BP CUGBP1 on 
the mRNA Su(H) that encodes a key player of Notch signalling. We showed that injecting this 
oligonucleotide into Xenopus embryos specifically inhibited the binding of CUGBP1 to the 
mRNA. This caused the derepression of Su(H) mRNA, the overexpression of Su(H) protein, 
and a phenotypic defect, loss of somitic segmentation, similar to that caused by a knockdown 
of CUGBP1. To demonstrate a causal relationship between Su(H) derepression and the 
segmentation defects, a rescue experiment was designed. Embryonic development was 
restored when the translation of Su(H) mRNA was re-repressed and the level of Su(H) protein 
was reduced to a normal level. This "target protector and rescue assay" demonstrates that the 
phenotypic defects associated with CUGBP1 inactivation in Xenopus are essentially due to 
the deregulation of Su(H) mRNA. Similar approaches may be largely used to uncover the 
links between the phenotype caused by the inactivation of an RNA-BP and the identity of the 
RNAs associated with that protein.  
 
 
 
 
Introduction 
The nuclear and cytoplasmic fates of eukaryotic mRNAs rely on interactions with a number 
of molecules, such as regulatory RNAs or proteins. RNA-Binding Proteins (RNA-BPs) play 
central roles in controlling events like premRNA maturation, mRNA nucleocytoplasmic 
export and cytoplasmic transport, translation, and degradation. Immunoprecipitations of some 
RNA-BPs and large-scale identification of co-immunoprecipitated mRNAs (by microarray 
hybridization or deep sequencing) showed that RNA-BPs are able to interact with a large 
number of target RNAs (Girard et al., 2006; Graindorge et al., 2008; Lopez de Silanes et al., 
2005; Lopez de Silanes et al., 2004; Stoecklin et al., 2008).  
Several gene inactivations or knock-down experiments of RNA-BPs have been published. 
These inactivations generally lead to huge phenotypic effects or even lethality. These 
phenotypic alterations may be caused by the deregulation of all, or at least most, of the 
mRNAs that are normally controlled by the inactivated RNA-BP. Alternatively, they may be 
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caused by the deregulation of only one or a limited number of them. For example, 
Tristetraprolin (TTP) directs bound mRNAs, including that encoding TNFα, to rapid 
degradation (Carballo et al., 1998). Mice in which the TTP gene was inactivated display 
several immunological defects, and they overexpress TNFα. Α treatment of these mice by 
neutralizing antibodies against TNFα efficiently cures them (Taylor et al., 1996), showing 
that derepression of TNFα mRNA is the main cause of the mutant phenotype associated with 
TTP inactivation. 
In contrast to the above example, we generally do not know how the inactivation of an RNA-
BP leads to phenotypic alterations, even for the RNA-BPs whose mRNA targets are known. 
To understand the molecular reasons for altered developmental phenotypes associated with 
inactivation of an RNA-BP, it is necessary to individually inhibit the regulation exerted by 
that factor on one of its RNA targets. Ideally, both the regulations exerted by that factor on its 
other mRNA targets, and the regulations exerted on that RNA by other factors, should remain 
intact.  
Here, we used the RNA-BP CUGBP1 (CUG-Binding Protein 1, formerly EDEN-BP in 
Xenopus) and the mRNA Su(H) (Suppressor of Hairless, an actor of Notch signalling) to test 
if morpholino antisense oligonucleotides can be used to specifically inhibit the interaction 
between a mRNA and a protein, and to analyse the phenotypical consequences of that 
inhibition. Knock-down of the RNA-BP CUGBP1 in Xenopus causes defects in somitic 
segmentation. Somitic segmentation is the developmental process that leads to the appearance 
of repeated units, the somites, along the embryonic antero-posterior axis. It is easy to score by 
external observation of the embryos. Su(H) mRNA is normally repressed by CUGBP1, and is 
overexpressed in CUGBP1 knock-down embryos (Gautier-Courteille et al., 2004). However, 
whether Su(H) derepression and segmentation defects are causally related remains an open 
question, as the knock-down of CUGBP1 may deregulate several mRNA targets of CUGBP1 
in addition to Su(H) (Graindorge et al., 2008). We showed here that a morpholino antisense 
oligonucleotide designed to prevent CUGBP1 from binding to Su(H) mRNA ("target 
protector", Choi et al., 2007) led to somitic defects similar to those caused by CUGBP1 
knock-down. A proof for the specificity of that effect was brought by a phenotypic rescue 
experiment. Hence, this "target-protector and rescue assay" (TPRA) demonstrated that 
derepression of Su(H) is the main cause of the phenotype associated with CUGBP1 loss-of-
function in Xenopus.  
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Results and discussion 
To identify the mRNA sequence element in Su(H) mRNA bound by CUGBP1, 5 RNAs 
corresponding to overlapping regions of the 3' Untranslated Region (3'UTR) were tested by 
EMSA (Electrophoretic Mobility Shift Assay). Figure 1A shows that only the RNA 
corresponding to region 495-631 of the 3'UTR (numbered from the stop codon) was bound by 
CUGBP1. The corresponding sequence is shown in Figure 1B. A hallmark of the EDEN 
sequences (sequences bound by CUGBP1) is their richness in trinucleotides UGU (Marquis et 
al., 2006). Five such UGUs are concentrated within a small subpart (highlighted in grey in 
Figure 1B) of region 495-631. No similar concentration of UGU is detected in any other 
region of Su(H) 3'UTR. A morpholino antisense oligonucleotide (α-SE, anti-Su(H) EDEN) 
was designed to hybridize to the putative EDEN of Su(H). In EMSA (Figure 1C, upper 
panel), the α-SE morpholino abolished the interaction between Su(H) RNA and CUGBP1 in a 
dose-dependent manner. To specificity of the α-SE morpholino was verified using Eg5 
3'UTR. This probe contains an EDEN whose sequence is different from Su(H) EDEN, 
although still UGU-rich 
(UAUAUAUGUGUGUCUAUCGUCACUUGUAUGUCAAAUAUU, UGUs are underlined) 
(Paillard et al., 1998).  In EMSA, even a large amount of α-SE morpholino had no effect on 
the interaction between CUGBP1 and Eg5 (Figure 1C, lower panel). Hence, α-SE is not a 
general inhibitor of CUGBP1 binding.  
We next analysed the in vivo effect of α-SE morpholino. First, we checked its effect on the 
interaction of CUGBP1 with Su(H) mRNA in undiluted Xenopus egg extracts. Cell-free 
cytoplasmic egg extracts are translationally active (Legagneux et al., 1995). CUGBP1 was 
immunoprecipitated from Xenopus egg extract previously incubated with control or α-SE 
morpholinos. The amounts of several co-immunoprecipitated mRNAs were quantified by 
real-time RT-PCR (Figure 1D). ODC mRNA, that is not known to bind CUGBP1, was 
recovered with the lowest efficiency of all the mRNAs tested. In contrast, Hete, Eg5, Eg2 and 
Su(H) mRNA, that were previously shown to interact with CUGBP1 (Graindorge et al., 
2008), were much more efficiently co-immunoprecipitated in the presence of the control 
morpholino. The amount of co-immunoprecipitated Su(H) was reduced more than two-fold by 
the α-SE morpholino, demonstrating that this morpholino decreases the interaction between 
Su(H) mRNA and CUGBP1 in egg extract. Furthermore, this effect was specific, as α-SE had 
virtually no effect on the amount of recovered Hete, Eg5 and Eg2 mRNA (Figure 1D). 
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Importantly, in that experiment, we measured the capacity of α-SE morpholino to disrupt a 
complex between CUGBP1 and Su(H) mRNA that already exists when the morpholino is 
added. We expect that the morpholino would be even more efficient in preventing the 
formation of that complex, for example with neo-synthesized mRNA.    
Since α-SE morpholino inhibits the interaction between CUGBP1 and Su(H) mRNA, and 
mRNAs that bind CUGBP1 are rapidly degraded, α-SE was expected to increase the steady-
state level of Su(H) mRNA. This was verified by injecting both blastomeres of two-cell 
embryos with α-SE morpholinos and then allowing them to develop. Analyses by RT-qPCR 
showed that, relative to the level of ODC mRNA, Su(H) mRNA level in α-SE embryos was 
significantly higher than in controls (Figure 2A). This was not the case for Eg5 mRNA 
(Figure 2A). Consistent with Su(H) mRNA overexpression, a Western analysis showed that, 
as normalized to the level of PCNA, Su(H) protein level was almost 3-fold higher in 
embryos injected with α-SE morpholino than in controls (Figure 2B).  
To analyse the phenotypic consequences of suppressing the down-regulation exerted by 
CUGBP1 on Su(H) mRNA, one blastomere of embryos at the 2-cell stage was injected with 
α-SE morpholino. Embryos were allowed to develop to tailbud stage. They were stained with 
the myotome-specific 12/101 monoclonal antibody (Kintner and Brockes, 1985) to make 
somites more visible. The side originating from the control (non-injected) blastomeres was 
generally similar to a non-injected control embryo (and similar to that shown in Figure 2C), 
but the side originating from the blastomere injected  with α-SE morpholino displayed one of 
three aspects. Figure 2C (unaffected) shows a normally segmented side with several chevron-
shaped somites along the antero-posterior axis. In Figure 2D (mildly affected), segmentation 
occurred normally in the anterior part of the embryo, but was abolished in the posterior-most 
region. Importantly, that region was still stained with the 12/101 antibody, demonstrating 
myotomal differentiation despite altered segmentation. Finally, in Figure 2E (strongly 
affected), there was no evidence for any segmentation process, despite myotomal 
differentiation. Respectively 80% and 19% of the embryos were strongly and mildly affected 
when 2 pmol of α-SE morpholino were injected (Figures 2C-E). We have shown previously 
that 90% of the embryos injected with a morpholino designed to knock-down CUGBP1 
display very similar segmentation defects (Gautier-Courteille et al., 2004).  
These data show that α-SE morpholino derepresses Su(H) mRNA, leading to an 
overexpression of Su(H) protein, and causes somitic segmentation defects. A likely 
hypothesis is that the derepression of Su(H) is indeed responsible for the phenotypic defects, 
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but, at this stage, off-target effects of the α-SE morpholino can not be excluded. Translating 
ribosomes are able to remove morpholinos hybridized within an mRNA coding frame. 
Consequently, only mRNA containing a site for α-SE in their untranslated regions can be 
considered as possible off-targets. A Blastn search of Xenopus laevis sequences (nr databank) 
using α-SE as the query sequence was made. In addition to Su(H), it retrieved two mRNAs 
that contain 15 consecutive nucleotides fully complementary to α-SE in their untranslated 
regions, mannose-binding lectin-associated serine protease-3a (accession number BC170241) 
and OLT 2-1 retrotransposon-like element 10A1 gag-like protein gene (AF145965). However, 
since sequencing of Xenopus laevis is not complete, other off-targets might also exist. 
A gold standard to rule out potential off-target effects is to design a rescue experiment. 
Classical rescue experiments consist of adding back a molecule that was previously depleted. 
Here, since a down-regulation is relieved, a rescue experiment consists of re-repressing the 
derepressed molecule. This was done by co-injecting, with the α-SE morpholino, a second 
morpholino ("α-SAUG") designed to inhibit the translation of Su(H) mRNA (Figure 3A). A 
Blastn search of Xenopus laevis sequences (nr databank) retrieved only one mRNA 
containing 15 consecutive nucleotides fully complementary to either of the two α-SAUG 
sequences (see Materials and Methods) in its untranslated regions, BRCA1 (NM_001090779), 
that is not a potential α-SE target. Figure 3B shows the percentages of unaffected, mildly, and 
strongly affected embryos after injection of different amounts of α-SE and α-SAUG. The 
percentage of normally segmented embryos decreased from 100% in control embryos to less 
than 10% upon injection of either amount of α-SE morpholino. However, in both cases, at 
least one amount of α-SAUG could be found that partly restored segmentation (60 and 100 
fmol for 2 pmol of α-SE, 100 fmol for 2.5 pmol of α-SE. p<0.001, χ2 test). We measured the 
levels of Su(H) mRNA and protein in these rescue conditions. Firstly, whereas α-SE caused a 
significant increase of Su(H) mRNA level as previously described, α-SAUG had no effect on 
that overexpression (Figure 3C). This was expected, since α-SAUG should block the 
translation of Su(H) mRNA without affecting its stability. Secondly, as anticipated, Su(H) 
protein level was decreased to a control level by the injection of α-SAUG in addition to α-SE 
(Figure 3D). Together, these data show that the effect of α-SE morpholino on somitic 
segmentation is due to a specific derepression of the down-regulation that is normally exerted 
by CUGBP1 on Su(H) mRNA. Furthermore, these data show that the phenotype associated 
with a knock-down of CUGBP1 in Xenopus embryos (Gautier-Courteille et al., 2004) is 
essentially due to a deregulation of Su(H) mRNA. 
 7 
The concept of "target protector" was initially developed in Zebrafish where it refers to an 
inhibition of the interaction between an mRNA and a miRNA (Choi et al., 2007; Li et al., 
2008). In these articles, an antisense oligonucleotide was injected that hybridized to the 
binding site of a miRNA on an mRNA, hence precluding interaction and leading to 
phenotypical consequences. The injected oligonucleotide should not activate RNase H that 
would destroy the targeted mRNA. For that reason, morpholino oligonucleotides were used in 
the above articles (Choi et al., 2007; Li et al., 2008) as well as in the present one. However, 
any modified oligonucleotide that does not activate RNase H would probably be suitable as a 
target protector. Irrespective of the modified oligonucleotide, we consider it important to 
design rescue experiments to exclude off-target effects of the target protector. In the present 
study, a normal phenotype was recovered by re-repressing the translation of the mRNA that 
was derepressed due to target protection, but the design of rescue experiments depends on 
each particular case. Potentially, "target protector and rescue assays" (TPRAs) could be used 
in any model system in which a target protector and a rescuing molecule can be introduced, 
such as Xenopus oocytes or embryos, Zebrafish, syncitial Drosophila embryos (by injection) 
or chick embryo (by electroporation). It should also allow analysing miRNA/mRNA 
interactions in addition to protein/mRNA interactions. Hence, TPRA could be widely used to 
understand the molecular reasons for altered developmental phenotypes associated with the 
inactivation of factors controlling mRNA fate. 
 
 
Materials and Methods 
Primer and morpholino sequences 
Morpholinos: Control CCTCTTACCTAGTTACAATTTATA; α-SE 
AAACGAAACAACACAAACAAAACAA; α-SAUG 
CCAGGTTGCATAGAACAATATGATG and GCCTCTCCCCAAACTTCATTCCGCT 
(sequence complementary to AUG initiation codon is underlined. As a consequence of 
Xenopus laevis genome tetraploidization, two highly related genes exist for Su(H). Two 
different morpholinos were therefore required to inhibit the translation of Su(H)).  
Primers used to generate transcription matrices (The T7 sequence for in vitro transcription 
is underlined): 
Su2_fwd_T7, 
 TAATACGACTCACTATAGGGAGACCATAAACTTTGGACTTTTACATGG 
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Su161_fwd_T7, 
 TAATACGACTCACTATAGGGAGACGTAGAAGCCACAATAATAAAATGGA 
Su375_fwd_T7,
 TAATACGACTCACTATAGGGAGAGTACAACTTTTGTTACCAAATAGAT 
Su495_fwd_T7,
 TAATACGACTCACTATAGGGAGAGATATATATATTTTGTGCAATGGCTGGC 
Su578_fwd_T7,
 TAATACGACTCACTATAGGGAGACCGAATGCTTTTTTTATGAACTG 
Su231_rev, TGCCCATTTTTGTAAAAATGCAGC 
Su431_rev, CTACACATACTTTAGAGCGC 
Su519_rev, GCCATTGCACAAAATATATATATC 
Su631_rev GGTTCTCAAATGCAGAAATAAAC 
Su717_rev GTAGACATCAATAGTTTGTATTGC 
Primers for qPCR 
Eg5_fwd GATCGGCACAGAGTTTTCGGT 
Eg5_rev  TTGTAGCCTTTCCCCGACATC 
ODC_fwd AAAATGGATGACTGCGAGATGGG 
ODC_rev AATGAAGATGCTGACTGGCAAAAC 
Su(H)_fwd GCCAGAGCCCGGACCTA 
Su(H)_rev TTGGATGCCAGGAGACTTGAA 
Eg2_fwd GGAGGTGGAAATTCAGTCCCA 
Eg2_rev GGCGCATAATCGAGGATTAGG 
Hete_fwd GGTGCTGAATGTGGCATTCTCT 
Hete_rev GCACACACGTTCTGGCAGATAC 
 
Biochemical methods 
For EMSAs (Marquis et al., 2006), 32P-labelled RNAs were obtained by T7 in vitro 
transcription from PCR products using a pGbSu(H) plasmid (Gautier-Courteille et al., 2004) 
with the appropriate primers, or a pGbsEg5 plasmid (Paillard et al., 1998), previously 
linearized with BamH1. Two-fold serial dilutions of recombinant CUGBP1 starting from 400 
nM, or three-fold serial dilutions of morpholino starting from 500 nM were used. 
For co-immunoprecipitation experiments, Xenopus egg extracts (Legagneux et al., 1995) were 
incubated for 1h at 22°C in the presence of 5 µM of control or α-SE morpholino and 
CUGBP1 was immunoprecipitated as described (Graindorge et al., 2008). After SDS elution, 
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RNA were extracted with Tri-reagent (Euromedex), and reverse-transcribed. The amount of 
RNA in each reverse-transcription reaction corresponded to the eluate of one 
immunoprecipitation experiment (from 40 µl of extract) or to 4 µl of total extract for the 
input. Real-time PCR were done in a final volume of 10 µl from 1/400 of these cDNAs using 
ABI Prism 7900 device (Applied), with the SybrGreen mastermix and 300 nM of each primer. 
For each RNA sample, quantifications were made in triplicate. 
The amounts of Su(H) and Eg5 mRNA in embryos were similarly quantified by RT-qPCR, 
after reverse-transcription of total embryo RNA. Each real-time PCR reaction was made from 
an amount of cDNA equivalent to 0.5 ng of total RNA. The amounts of Su(H) and Eg5 
mRNA in embryos were calculated as 2ΔCt relative to the amount of ODC mRNA. 
Western blots were made and revealed by ECL as previously described (Gautier-Courteille et 
al., 2004). They were quantified by densitometry. The primary antibodies were anti-
mammalian RBP-Jκ (mammalian orthologue of Su(H), Chemicon AB5790) and anti-PCNA 
(Sigma P8825). 
  
Xenopus laevis embryos procedures  
One or two blastomeres of embryos at the two-cell stage were injected with 0-5 pmol of 
morpholino. They were allowed to develop at 16°C overnight then at 22°C for 1 day (to stage 
24-26), fixed with MEMFA and immunostained with the 12/101 monoclonal antibody 
(Kintner and Brockes, 1985) as described (Gautier-Courteille et al., 2004). Stained embryos 
were blind sorted (the person sorting embryos did not know what had been injected) 
according to their phenotypes (unaffected to strongly affected embryos).  
 
Acknowledgments 
We thank H Beverley Osborne, Serge Hardy and members of the EGD team for discussions. 
This work was supported by grants from the Association pour la Recherche Contre le Cancer 
(ARC4003 to LP) and Agence Nationale de la Recherche (ANR-07-JCJC-0097-01 to LP). 
 
 
References 
Carballo E, Lai WS, Blackshear PJ. 1998. Feedback inhibition of macrophage tumor necrosis 
factor-alpha production by tristetraprolin. Science 281: 1001-1005. 
 10
Choi WY, Giraldez AJ, Schier AF. 2007. Target protectors reveal dampening and balancing 
of Nodal agonist and antagonist by miR-430. Science 318: 271-274. 
Gautier-Courteille C, Le Clainche C, Barreau C, Audic Y, Graindorge A, Maniey D, Osborne 
HB, Paillard L. 2004. EDEN-BP-dependent post-transcriptional regulation of gene 
expression in Xenopus somitic segmentation. Development 131: 6107-6117. 
Girard A, Sachidanandam R, Hannon GJ, Carmell MA. 2006. A germline-specific class of 
small RNAs binds mammalian Piwi proteins. Nature 442: 199-202. 
Graindorge A, Le Tonqueze O, Thuret R, Pollet N, Osborne HB, Audic Y. 2008. 
Identification of CUG-BP1/EDEN-BP target mRNAs in Xenopus tropicalis. Nucleic Acids 
Res. 36: 1861-70. 
Graindorge A, Thuret R, Pollet N, Osborne HB, Audic Y. 2006. Identification of post-
transcriptionally regulated Xenopus tropicalis maternal mRNAs by microarray. Nucleic 
Acids Res 34: 986-995. 
Kintner CR, Brockes JP. 1985. Monoclonal antibodies to the cells of a regenerating limb. J 
Embryol Exp Morphol 89: 37-55. 
Legagneux V, Omilli F, Osborne HB. 1995. Substrate-specific regulation of RNA 
deadenylation in Xenopus embryo and activated egg extracts. RNA 1: 1001-1008. 
Li N, Flynt AS, Kim HR, Solnica-Krezel L, Patton JG. 2008. Dispatched Homolog 2 is 
targeted by miR-214 through a combination of three weak microRNA recognition sites. 
Nucleic Acids Res 36: 4277-4285. 
Lopez de Silanes I, Galban S, Martindale JL, Yang X, Mazan-Mamczarz K, Indig FE, Falco 
G, Zhan M, Gorospe M. 2005. Identification and Functional Outcome of mRNAs 
Associated with RNA-Binding Protein TIA-1. Mol Cell Biol 25: 9520-9531. 
Lopez de Silanes I, Zhan M, Lal A, Yang X, Gorospe M. 2004. Identification of a target RNA 
motif for RNA-binding protein HuR. Proc Natl Acad Sci U S A 101: 2987-2992. 
Marquis J, Paillard L, Audic Y, Cosson B, Danos O, Le Bec C, Osborne HB. 2006. CUG-
BP1/CELF1 requires UGU-rich sequences for high-affinity binding. Biochem J 400: 291-
301. 
Paillard L, Omilli F, Legagneux V, Bassez T, Maniey D, Osborne HB. 1998. EDEN and 
EDEN-BP, a cis element and an associated factor that mediates sequence-specific mRNA 
deadenylation in Xenopus embryos. EMBO J 17: 278-287. 
Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD, Baroni TE, Blackshear PJ, 
Anderson P. 2008. Genome-wide analysis identifies interleukin-10 mRNA as target of 
tristetraprolin. J Biol Chem 283: 11689-11699. 
 11
Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson 
GS, Broxmeyer HE, Haynes BF, et al. 1996. A pathogenetic role for TNF alpha in the 
syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) 
deficiency. Immunity 4: 445-454. 
 
 
 12
Legend to figures 
 
Figure 1. Design of a morpholino antisense oligonucleotide ("α-SE") that precludes the 
interaction between Su(H) and CUGBP1. A, In vitro transcribed radioactive RNAs 
corresponding to the indicated regions of Su(H) 3'UTR (numbered from the stop codon) were 
incubated with no (lane 1) or increasing amounts (lanes 2-9) of recombinant CUGBP1. Free 
(F) and bound (B) RNAs were resolved by native electrophoresis and autoradiographed. B, 
Sequence of Su(H) 3'UTR between nucleotides 495 and 631 (numbered from the stop codon). 
UGU trinucleotides are underlined, and the region complementary to α-SE morpholino is 
highlighted. C, Radioactive RNAs corresponding to region 495-631 of Su(H) 3'UTR (upper 
panel) or Eg5 3'UTR (lower panel) were incubated with no (lanes 1) or 50 nM (lanes 2-10) of 
recombinant CUGBP1, and increasing concentrations of α-SE morpholino (lanes 3-10). They 
were analysed as in A. D, CUGBP1 was immunoprecipitated from Xenopus egg extracts 
previously incubated with 5 µM of control (dark grey) or α-SE (light grey) morpholino. The 
indicated input and co-immunoprecipitated mRNAs were quantified by RT-qPCR. The 
percentages of mRNA recovered in the immunoprecipitated fractions are shown. 
Quantifications were in triplicate and error bars are the s.e. of the triplicates. 
 
Figure 2. α-SE morpholino derepresses endogenous Su(H) mRNA and causes 
segmentation defects. A and B, Xenopus embryos at the two-cell stage were injected with 2 
pmol of control or anti-Su(H) EDEN morpholino (α-SE) in each blastomere. They were 
allowed to develop until the tailbud stage (24-26). A, RNAs were extracted and the amounts 
of Su(H) and Eg5 mRNA, relative to the amount of ODC mRNA, were measured by RT-
qPCR. Shown are the medians, +/- s.e., of 15 embryos for each condition. Student tests were 
used to compare control and α-SE morpholinos, and p values are indicated above the bars. B, 
Proteins were extracted from pools of 5 embryos and 1 embryo equivalent was submitted to a 
Western analysis using antibodies directed against Su(H) and PCNA as a loading control. 
Positions of molecular weight markers are indicated on the right. C-E, Two-cell embryos 
were injected in one blastomere with 2 pmol of anti-Su(H) EDEN morpholino (α-SE) and 
allowed to develop until tailbud stage. They were fixed and stained with myotome-specific 
12/101 monoclonal antibody. C, D and E are, respectively, representative photographs of an 
unaffected embryo, an embryo with a progressive loss of segmentation toward the posterior 
extremity, and a non-segmented embryo. Lower panels are higher magnifications of upper 
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panels. In C and D, lower panels, stars show successive somites. The number of embryos that 
fell within each class in one representative experiment is given on bottom. 
 
Figure 3. Phenotypic rescue of α-SE morpholino provided by repression of Su(H) 
mRNA. A, Design of a "rescue" experiment. In control embryos (upper panel), Su(H) mRNA 
is bound by CUGBP1, leading to a rapid degradation of the mRNA. The α-SE morpholino 
(middle panel) prevents CUGBP1 binding to Su(H) mRNA, hence stabilizes it, leading to 
protein overexpression. It also leads to phenotypic defects. If these phenotypic defects are 
specifically due to the derepression of Su(H) mRNA, then development should be restored by 
injecting an adequate amount of a second morpholino directed against the translation 
initiation region (α-SAUG, lower panel), which, by reducing translation, will reduce the 
amount of Su(H) protein to a normal level. B is a quantification of segmentation defects. 
Embryos were co-injected with the indicated amounts of α-SE morpholino and 0, 10, 60 or 
100 fmol of α-SAUG. Embryos were sorted at stage 24-26 according to their phenotype: 
unaffected (like in Figure 2C, black), mild (like in Figure 2D, dark grey) or strong (like in 
Figure 2E, light grey). The total number of sorted embryos for each combination of 
morpholinos is indicated. C and D, Xenopus embryos at the two-cell stage were injected in 
each blastomere with 2 pmol of control morpholino (lane 1) or 2 pmol of α-SE morpholino in 
the absence (lane 2) or the presence (lane 3) of 60 fmol of α-SAUG morpholino. They were 
allowed to develop until the tailbud stage (24-26). RNA (C) and protein (D) levels were 
analysed as in Figure 2 A-B.  
 
 



